Isigebenga samayeza uLilly, inkampani yaseMelika, kunye neNovo Nordisk, inkampani yaseDenmark, baye babhengeza ngokulandelelana idatha yokuthengisa yeemveliso zabo eziphambili ngo-2020: iDulaglutide iye yaba lichiza le-TOP1 GLP-1, kunye nentengiso ye-5.07Bn ngo-2020, unyaka- ukunyuka konyaka ngama-22.8%;i-liraglutide Ukuqala ukungena kwixesha lokuhla, ukuthengisa ngo-2020 kwehle ukusuka kwi-4.14Bn ukuya kwi-3.93Bn ye-3.93Bn, ukwehla konyaka-ngonyaka we-5.1%;I-semaglutide ikhule ngokukhawuleza, kunye neentengiso ezifikelela kwi-$ 3.72Bn kwi-2020, ukunyuka konyaka-ngonyaka we-119.9%.
I-Dulaglutide ka-Lilly (igama lorhwebo i-Trulicity®) yasungulwa ngo-2014 kwaye yaba lichiza le-blockbuster elinentengiso ye-5.07Bn kwiminyaka nje emi-6, yaba yintshatsheli yokuthengisa yamachiza e-GLP-1.Imveliso enye yeNovo Nordisk iye yasala okwethutyana emva kweLilly.I-liraglutide yayo (igama lorhwebo iVictoza® kunye neSaxenda®), eyasungulwa ngo-2009, yayikhe yaba yintshatsheli yokuthengisa iziyobisi ze-GLP-1, kwaye intengiso yayo ephezulu ngo-2017 yafikelela kwi-4.37 yezigidigidi zeedola, nangona kukho iimpawu ezimbini zohlobo lwesifo seswekile kunye nokutyeba. , idatha ye-2020 ibonisa ukuba imarike yeli chiza ingene kwixesha lokuhla.I-semaglutide ye-Novo Nordisk efanayo (amagama okurhweba i-Ozempic® kunye ne-Rybelsus®) ikhule ngokukhawuleza kwaye ikhule yaba sesinye isidakamizwa se-blockbuster kunye neentengiso ze-3.72Bn kwiminyaka emithathu.Ichiza lineendlela ezimbini zedosi yesitofu kunye namalungiselelo omlomo.
Ukusuka kwimbono yejografi, iUnited States lelona lizwe liphambili lokuthengisa le-liraglutide, libalelwa phantse kwi-60% ngo-2020, ukuhla konyaka-ngonyaka kwe-11.02%;ikwakukudodobala koqoqosho e-United States okubangele ukwehla kwemarike yehlabathi ye-liraglutide.Ummandla we-EMEA (iYurophu, uMbindi Mpuma, i-Afrika) ukhule kancinci, kunye ne-CAGR ye-1.6% kuphela kwiminyaka emihlanu edlulileyo;I-China yeyona marike ikhula ngokukhawuleza, kunye nentengiso ye-182.50 yezigidi zeedola ngo-2020, kunye nezinga lokukhula lonyaka elihlanganisiweyo le-42.39%.Ekubeni i-semaglutide sele ikhona kwimarike ngokukhawuleza, zonke iimarike zikwinqanaba lokukhula ngokukhawuleza.I-United States iseyeyona marike inkulu, ibala i-80.04% yokuthengisa kwi-2020, ukunyuka konyaka-ngonyaka we-106.08%;I-EMEA inesabelo se-13.64% kuphela kodwa izinga lokukhula konyaka-ngonyaka we-249.65% .I-Semaglutide yasungulwa e-China kwi-2020 kunye neentengiso ze-1.61Mn.Umzobo 3 ubonisa imeko yengingqi ye dulaglutide.Njengeyona marike inkulu, iUnited States ineentengiso ezifikelela kwi-3.836 yezigidigidi zeedola, ezibalelwa kwi-75.69%, kunye nezinga lokukhula lonyaka elihlanganisiweyo le-79.18%.
Awona malungelo abenzi angundoqo we-liraglutide (i-Victoza® kunye ne-Saxenda®) iphelelwe lixesha e-China kwaye sele iza kuphelelwa e-US, e-Japan nase-Jamani.Idabi lelungelo elilodwa lomenzi kaTeva kunye noNovo Nordisk sele lilungisiwe, kwaye inguqulelo yegeneric kaTeva iya kufumaneka ngo-2023. U-Mylan uphinde wafaka isicelo se-ANDA kunye ne-FDA ye-liraglutide kunye nebango le-PIV.Ngokuphelelwa kancinci kwamalungelo awodwa abenzi kunye nogrogriso lwabenzi bamachiza enziwe afana nalawo aveliswe ngumenzi, ichiza liyakungena kancinane kwixesha lokwehla.I-patent yase-US ye-Trulicity® ayiyi kuphelelwa yisikhathi kude kube ngu-2027, ngelixa i-patent yamazwe aseYurophu kunye ne-Japan ayiyi kuphelelwa yisikhathi kude kube ngu-2029, kwaye ukhuseleko oluphambili lwe-patent lude kune-liraglutide.I-patent engundoqo ye-semaglutide (i-Ozempic® kunye ne-Rybelsus®) iya kuphelelwa yisikhathi kwi-2032 kwangoku, kwaye kusekho indawo enkulu yokukhula kweemarike, kodwa ixesha lokuphelelwa kwayo e-China yi-2026.
Ixesha lokuposa: Jul-25-2022